Hepatitis Acute Articles & Analysis
3 news found
– AMVUTTRA Demonstrated Halting or Reversal in Neuropathy Impairment with Subcutaneous Administration Once Every Three Months – – Decision Follows Positive Opinion from the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) in July 2022 – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 20, 2022-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), ...
However, intravenous treatment with the necessary dose of tigecycline (200 mg/day) has severe side effects, including excessive vomiting, hepatic dysfunction and acute pancreatitis. In order to overcome this obstacle, Radboudumc also researched inhaled administration of tigecycline. ...
Fatalities due to adverse reactions occurred in 4.3% of patients including interstitial lung disease (2.6%), and the following events occurred in one patient each (0.4%): acute hepatic failure/acute kidney injury, general physical health deterioration, pneumonia, and hemorrhagic shock. ...